Notice of Annual General Meeting in CellaVision AB, April 24, 2013
The shareholders in CellaVision AB are hereby summoned to the Annual General Meeting, to be held on April 24, 2013 at 16.00 at CellaVision AB, Scheelevägen 19 A, Ideon, in Lund, Sweden.
The complete notice is available in Swedish only, please click the link below.
For more information, please contact:
Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82
e-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In most countries sales are via global partners. Products are sold directly in the Nordic countries and via subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.
The complete notice is available in Swedish only, please click the link below.
For more information, please contact:
Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82
e-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In most countries sales are via global partners. Products are sold directly in the Nordic countries and via subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.